Antengene Corporation Limited (HK:6996) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Antengene Corporation Limited has announced that its drug XPOVIO, used to treat relapsed or refractory diffuse large B-cell lymphoma, will be included in China’s 2024 National Reimbursement Drug List. This inclusion marks a significant milestone for Antengene, potentially enhancing its market presence and financial performance. Investors and shareholders may find this development promising as it could lead to increased adoption and sales of XPOVIO in the region.
For further insights into HK:6996 stock, check out TipRanks’ Stock Analysis page.